CellMax is developing and applying its CTC platform for early detection of colorectal cancer and more long term for breast and prostate cancer.
The company said it completed approximately 292,000 Cologuard tests during the fourth quarter.
The team will combine CellMax's circulating tumor cell platform and Medigen's liquid biopsy panel to track treatment response in colorectal cancer patients.
The firm has struggled in the past to convince payors of its test's clinical utility but remains dedicated to convincing the field that Epi proColon can help patients by closing CRC screening gaps.
The new services geared toward wellness testing enable patients to order test kits without visiting their doctor.
Researchers separately found that the assay had high concordance with other techniques in cancers including colorectal and endometrial carcinomas.
Under the five-year agreement extension, Quest will continue to provide broad access to Clinical Genomics's InSure One fecal immunochemical test in the US.
Test volume for the firm's Cologuard colorectal cancer screening test rose 49 percent year over year during the quarter.
The firm plans to conduct a prospective trial of a pan cancer assay and aims to bring another assay focused on colorectal cancer through FDA clearance.
The measures are part of a long-term plan for the National Health Service that will be rolled out across the country to detect 3 out of every 4 cancers at an early stage.